IBIO
iBio, Inc.
Key Financials
Operating Income
$-35141000
↓ 88.9%
Revenue
$100000
↓ 75.0%
Net Income
$-33044000
↓ 79.8%
Total Assets
$99.1M
↑ 327.5%
EPS (Diluted)
$-0.32
↑ 81.7%
Total Liabilities
$13.4M
↑ 61.3%
Cash & Equivalents
$56.4M
↑ 557.1%
Gross Profit
$2.2M
↑ 138.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/14/2026 | View on SEC |
| ARS | 9/4/2026 | View on SEC |
| DEF 14A | 9/4/2026 | View on SEC |
| 10-K | 8/28/2026 | View on SEC |
| 8-K | 8/28/2026 | View on SEC |
| PRE 14A | 8/20/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IBIO |
| Company Name | iBio, Inc. |
| CIK | 1420720 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0630 |
| State of Incorporation | DE |
| Phone | 302 355-0650 |